Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ)
- Previous Close
16.18 - Open
16.69 - Bid 16.17 x --
- Ask 16.18 x --
- Day's Range
16.11 - 16.38 - 52 Week Range
14.10 - 19.44 - Volume
1,498,628 - Avg. Volume
1,945,252 - Market Cap (intraday)
4.17B - Beta (5Y Monthly) 0.14
- PE Ratio (TTM)
23.11 - EPS (TTM)
0.70 - Earnings Date --
- Forward Dividend & Yield 0.35 (2.16%)
- Ex-Dividend Date Apr 29, 2025
- 1y Target Est
--
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. It offers its products in various forms comprising tablets, soft capsules, granules, flat films, pills, mixture, and injection for use in various therapeutic fields, such as nervous system, musculoskeletal, genitourinary system, antineoplastic and immune system, sensory system, systemic anti-infection, respiratory system, endocrine system, digestive system, and cardiovascular system, as well as drugs for invigorating qi and blood. The company also provides Chinese and Western tablets, capsules, oral liquids, granules, biological agents, and APIs. It also exports its products. The company was founded in 1951 and is based in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Jinhao Pharmaceutical Co., Ltd.
www.lishengpharma.com1,604
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 002393.SZ
View MorePerformance Overview: 002393.SZ
Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002393.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002393.SZ
View MoreValuation Measures
Market Cap
4.17B
Enterprise Value
2.09B
Trailing P/E
23.11
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.11
Price/Book (mrq)
0.87
Enterprise Value/Revenue
1.56
Enterprise Value/EBITDA
9.48
Financial Highlights
Profitability and Income Statement
Profit Margin
13.47%
Return on Assets (ttm)
0.77%
Return on Equity (ttm)
3.80%
Revenue (ttm)
1.34B
Net Income Avi to Common (ttm)
180.65M
Diluted EPS (ttm)
0.70
Balance Sheet and Cash Flow
Total Cash (mrq)
2.12B
Total Debt/Equity (mrq)
0.83%
Levered Free Cash Flow (ttm)
-39.86M